Salix Pharmaceuticals, Inc. (SLXP) - Financial and Strategic SWOT Analysis Review

Document Sample
Salix Pharmaceuticals, Inc. (SLXP) - Financial and Strategic SWOT Analysis Review Powered By Docstoc
					              Salix Pharmaceuticals, Inc. (SLXP) - Financial and Strategic SWOT
                                       Analysis Review
        Reference Code: GDPH32717FSA                                                                                          Publication Date: MAR 2013

          8510 Colonnade Center Drive                        Phone              +1 919 8621000                  Revenue          540.5 (million USD)
          Raleigh, NC                                        Fax                +1 919 8621095                  Net Profit       87.40 (million USD)
          27615                                              Website            www.salix.com                   Employees        235
                                                                                                                                 Pharmaceuticals           &
          United States                                      Exchange           SLXP [NASDAQ]                   Industry
                                                                                                                                 Healthcare

       Company Overview
       Salix Pharmaceuticals, Inc. (Salix) is a specialty pharmaceutical company. It develops and markets prescription pharmaceutical
       products for the prevention and treatment of gastrointestinal diseases. The company also in- licenses late-stage and marketed
       proprietary therapeutic products. The products offered by the company include Xifaxan, Moviprep, Osmoprep, Visicol, Colazal,
       Apriso and others. Xifaxan is a gastrointestinal-specific oral antibiotic and highest revenue generating drug of the company.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Salix Pharmaceuticals, Inc., SWOT Analysis
         Carolyn J. Logan                    Chief Executive Officer                  Strengths                              Weaknesses
         John F. Chappell                    Director
                                                                                                                             Dependence on Third Party
         Thomas D'Alonzo                     Chairman                                 Lead Product: Xifaxan
                                                                                                                             Manufacturers
         Richard A. Franco                   Director                                 Licensing Partnerships
                                                                                                                             Legal Proceedings
         William P. Keane                    Director
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Opportunities                          Threats

       Share Data                                                                     Strategic Initiatives                  Uncertain R&D Outcomes
         Salix Pharmaceuticals, Inc.
                                                                                      Pipeline Products                      Increased Pricing Control
        Share Price (USD) as on 15-Mar-                                49.51
        2013
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (USD)                                                        1.44        GlobalData
        Market Cap (million USD)                                       2,913
        Enterprise Value (million USD)                                 3,006
        Shares Outstanding (million)                                       59
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Nov 07, 2012         Salix Pharma Reports Revenue Of $185.1m In
                                                                                                           Q3 2012
                                                                                      Sep 20, 2012         Progenics Pharma Reduces Workforce By
                                                                                                           26%
                                                                                      May 18, 2012         Salix Outlines Data Presentations At Digestive
                                                                                                           Disease Week
                                                                                      May 07, 2012         Salix Pharma Reports Revenue Of $171.1m In
                                                                                                           Q1 2012
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Salix Pharmaceuticals, Inc. (SLXP) - Financial and Strategic SWOT                                                              Reference Code: GDPH32717FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Salix Pharmaceuticals, Inc. - Key Facts ............................................................................................................................................. 5
       Salix Pharmaceuticals, Inc. - Key Employees .................................................................................................................................... 6
       Salix Pharmaceuticals, Inc. - Key Employee Biographies .................................................................................................................. 7
       Salix Pharmaceuticals, Inc. - Major Products and Services................................................................................................................ 8
       Salix Pharmaceuticals, Inc. - History .................................................................................................................................................. 9
       Salix Pharmaceuticals, Inc. - Company Statement........................................................................................................................... 12
       Salix Pharmaceuticals, Inc. - Locations And Subsidiaries ................................................................................................................ 14
          Head Office ................................................................................................................................................................................... 14
          Other Locations & Subsidiaries ..................................................................................................................................................... 14
       Section 2 – Company Analysis ......................................................................................................................................................... 15
       Salix Pharmaceuticals, Inc. - Business Description .......................................................................................................................... 15
       Salix Pharmaceuticals, Inc. - Corporate Strategy ............................................................................................................................. 16
       Salix Pharmaceuticals, Inc. - SWOT Analysis .................................................................................................................................. 17
          SWOT Analysis - Overview........................................................................................................................................................... 17
          Salix Pharmaceuticals, Inc. - Strengths ........................................................................................................................................ 17
             Strength - Lead Product: Xifaxan .............................................................................................................................................. 17
             Strength - Licensing Partnerships ............................................................................................................................................. 17
          Salix Pharmaceuticals, Inc. - Weaknesses ................................................................................................................................... 17
             Weakness - Dependence on Third Party Manufacturers ........................................................................................................... 17
             Weakness - Legal Proceedings ................................................................................................................................................. 17
          Salix Pharmaceuticals, Inc. - Opportunities .................................................................................................................................. 18
             Opportunity - Strategic Initiatives .............................................................................................................................................. 18
             Opportunity - Pipeline Products ................................................................................................................................................. 18
             Opportunity - Market Potential - Gastrointestinal Disorders ...................................................................................................... 18
          Salix Pharmaceuticals, Inc. - Threats............................................................................................................................................ 18
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 18
             Threat - Increased Pricing Control............................................................................................................................................. 19
             Threat - Highly Competitive Markets ......................................................................................................................................... 19
       Salix Pharmaceuticals, Inc. - Key Competitors ................................................................................................................................. 20
       Section 3 – Company Financial Ratios ............................................................................................................................................. 21
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 21
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 21
       Performance Chart ........................................................................................................................................................................... 23
       Financial Performance...................................................................................................................................................................... 23
       Financial Ratios - Interim Ratios....................................................................................................................................................... 24
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 25
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 26
          Salix Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 ................................................. 26
          Salix Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013................................................. 27
          Salix Pharmaceuticals, Inc., Medical Equipment, Deals By Year, 2007 to YTD 2013................................................................... 28
          Salix Pharmaceuticals, Inc., Medical Equipment, Deals By Type, 2007 to YTD 2013 .................................................................. 29


Salix Pharmaceuticals, Inc. (SLXP) - Financial and Strategic SWOT                                                                                              Reference Code: GDPH32717FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Salix Pharmaceuticals, Inc., Recent Deals Summary....................................................................................................................... 30
       Section 5 – Company’s Recent Developments ................................................................................................................................ 31
          Salix Pharmaceuticals, Inc., Recent Developments...................................................................................................................... 31
             Nov 07, 2012: Salix Pharma Reports Revenue Of $185.1m In Q3 2012................................................................................... 31
             Sep 20, 2012: Progenics Pharma Reduces Workforce By 26% ................................................................................................ 31
             May 18, 2012: Salix Outlines Data Presentations At Digestive Disease Week .................................................................
				
DOCUMENT INFO
Description: Salix Pharmaceuticals, Inc. (Salix) is a specialty pharmaceutical company. It develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal diseases. The company also in- licenses late-stage and marketed proprietary therapeutic products. The products offered by the company include Xifaxan, Moviprep, Osmoprep, Visicol, Colazal, Apriso and others. Xifaxan is a gastrointestinal-specific oral antibiotic and highest revenue generating drug of the company.
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.